BioSpace News Archive

Only 25 percent of beneficiaries say that plan provides personalized incentives

Cologuard test volume increased 64 percent, with approximately 934,000 tests completed in 2018

3SBio Inc. announced today that it has entered into a collaboration agreement with Samsung Bioepis Co., Ltd. for the clinical development and commercialization of multiple biosimilar candidates developed by Samsung Bioepis, including SB8 Bevacizumab biosimilar candidate (“SB8") in Mainland China (excluding Hong Kong, Macau and Taiwan).

Added 117 commercially contracted U.S. instruments in Q4, doubling the regional installed base

Artificial Intelligence (AI)-powered applications will help predict how individual patients will respond to immunotherapies in advance of treatment

Teva Pharmaceutical Industries today announced that members of management will present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 09:30AM PST (12:30PM EST).

Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding

PAREXEL International Corporation today introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.

INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $130 Million with Approximately 22,900 TRx

The Global Beauty Leader Furthers its Commitment to Skincare Science and Personalization with My Skin Track pH by La Roche-Posay--a Groundbreaking New Way to Understand Skin Health